117 related articles for article (PubMed ID: 21747954)
1. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice.
Meng T; Kolpe AB; Kiener TK; Chow VT; Kwang J
PLoS One; 2011; 6(7):e21757. PubMed ID: 21747954
[TBL] [Abstract][Full Text] [Related]
2. Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice.
Premanand B; Prabakaran M; Kiener TK; Kwang J
PLoS One; 2013; 8(2):e55536. PubMed ID: 23390538
[TBL] [Abstract][Full Text] [Related]
3. VP1 codon deoptimization and high-fidelity substitutions in 3D polymerase as potential vaccine strategies for eliciting immune responses against enterovirus A71.
Hsieh W-S; Chao C-H; Shen C-Y; Cheng D; Huang S-W; Wang Y-F; Chen C-C; Chen S-H; Hsu L-J; Wang J-R
J Virol; 2024 Jan; 98(1):e0155823. PubMed ID: 38174926
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and genotypic characteristics of novel mouse cell line (NIH/3T3)-adapted human enterovirus 71 strains (EV71:TLLm and EV71:TLLmv).
Victorio CB; Xu Y; Ng Q; Chow VT; Chua KB
PLoS One; 2014; 9(3):e92719. PubMed ID: 24671184
[TBL] [Abstract][Full Text] [Related]
5. Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71.
Huang KA; Zhou D; Fry EE; Kotecha A; Huang PN; Yang SL; Tsao KC; Huang YC; Lin TY; Ren J; Stuart DI
Nat Commun; 2020 Oct; 11(1):5253. PubMed ID: 33067459
[TBL] [Abstract][Full Text] [Related]
6. Monitoring antigenic variations of enterovirus 71: implications for virus surveillance and vaccine development.
Chia MY; Chung WY; Chiang PS; Chien YS; Ho MS; Lee MS
PLoS Negl Trop Dis; 2014 Jul; 8(7):e3044. PubMed ID: 25058733
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine.
Hwa SH; Lee YA; Brewoo JN; Partidos CD; Osorio JE; Santangelo JD
PLoS Negl Trop Dis; 2013 Nov; 7(11):e2538. PubMed ID: 24244774
[TBL] [Abstract][Full Text] [Related]
8. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection.
Cordey S; Petty TJ; Schibler M; Martinez Y; Gerlach D; van Belle S; Turin L; Zdobnov E; Kaiser L; Tapparel C
PLoS Pathog; 2012; 8(7):e1002826. PubMed ID: 22910880
[TBL] [Abstract][Full Text] [Related]
9. The 3' end of Norwalk virus mRNA contains determinants that regulate the expression and stability of the viral capsid protein VP1: a novel function for the VP2 protein.
Bertolotti-Ciarlet A; Crawford SE; Hutson AM; Estes MK
J Virol; 2003 Nov; 77(21):11603-15. PubMed ID: 14557646
[TBL] [Abstract][Full Text] [Related]
10. Human IgG Fc promotes expression, secretion and immunogenicity of enterovirus 71 VP1 protein.
Xu J; Zhang C
J Biomed Res; 2016 May; 30(3):209-16. PubMed ID: 27533931
[TBL] [Abstract][Full Text] [Related]
11. Cell surface vimentin is an attachment receptor for enterovirus 71.
Du N; Cong H; Tian H; Zhang H; Zhang W; Song L; Tien P
J Virol; 2014 May; 88(10):5816-33. PubMed ID: 24623428
[TBL] [Abstract][Full Text] [Related]
12. Baculovirus Surface Display of Immunogenic Proteins for Vaccine Development.
Premanand B; Zhong Wee P; Prabakaran M
Viruses; 2018 May; 10(6):. PubMed ID: 29857561
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based tetravalent vaccine against four major enteroviruses causing hand, foot, and mouth disease.
Maje Bello A; Chaimongkolnukul K; Poomputsa K; Mekvichitsaeng P; Maprang Roshorm Y
Vaccine; 2024 May; ():. PubMed ID: 38705805
[TBL] [Abstract][Full Text] [Related]
14.
Tao LN; Liu ZH; Xu HL; Lu Y; Liao M; He F
Vaccines (Basel); 2020 Sep; 8(3):. PubMed ID: 32911686
[TBL] [Abstract][Full Text] [Related]
15. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
16. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein.
Kiener TK; Jia Q; Meng T; Chow VT; Kwang J
PLoS Negl Trop Dis; 2014; 8(5):e2895. PubMed ID: 24875055
[TBL] [Abstract][Full Text] [Related]
17. Identification of a common epitope between enterovirus 71 and human MED25 proteins which may explain virus-associated neurological disease.
Fan P; Li X; Sun S; Su W; An D; Gao F; Kong W; Jiang C
Viruses; 2015 Mar; 7(4):1558-77. PubMed ID: 25826188
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of enterovirus 71 (EV71) recombinant virus particles provide insights into vaccine design.
Lyu K; Wang GC; He YL; Han JF; Ye Q; Qin CF; Chen R
J Biol Chem; 2015 Feb; 290(6):3198-208. PubMed ID: 25492868
[TBL] [Abstract][Full Text] [Related]
19. The enterovirus 71 procapsid binds neutralizing antibodies and rescues virus infection in vitro.
Shingler KL; Cifuente JO; Ashley RE; Makhov AM; Conway JF; Hafenstein S
J Virol; 2015 Feb; 89(3):1900-8. PubMed ID: 25428877
[TBL] [Abstract][Full Text] [Related]
20. Antigenic characteristics of the complete and truncated capsid protein VP1 of enterovirus 71.
Zhang J; Dong M; Jiang B; Dai X; Meng J
Virus Res; 2012 Aug; 167(2):337-42. PubMed ID: 22659489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
